GMAB is expected to report earnings to rise 313.13% to 34 cents per share on August 06
Q2'26
Est.
$0.34
Q1'26
Missed
by $0.09
Q4'25
Beat
by $14.94
Q3'25
Beat
by $0.18
Q2'25
Beat
by $0.15
The last earnings report on May 07 showed earnings per share of 8 cents, missing the estimate of 17 cents. With 654.44K shares outstanding, the current market capitalization sits at 15.37B.
A.I. Advisor
published General Information
General Information
an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.
GMAB's RSI Indicator ascending out of oversold territory
The RSI Indicator for GMAB moved out of oversold territory on June 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In of the 47 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where GMAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
GMAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMAB as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GMAB turned negative on June 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
GMAB moved below its 50-day moving average on May 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for GMAB entered a downward trend on June 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GMAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.679) is normal, around the industry mean (19.523). P/E Ratio (18.852) is within average values for comparable stocks, (35.904). Projected Growth (PEG Ratio) (1.644) is also within normal values, averaging (1.680). GMAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (3.982) is also within normal values, averaging (353.959).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
